Divine Aleru, Microbiome Signatures Research Coordinator

This case–control study links high copper and low molybdenum levels to metabolic, hormonal, and inflammatory changes in PCOS. Dietary habits influenced these levels, suggesting potential for targeted nutritional interventions.

This study links elevated arsenic, cadmium, lead, and mercury levels to oxidative stress and low antioxidant defenses in PCOS patients, highlighting heavy metal toxicity as a key contributor to endocrine dysfunction and microbiome imbalance.

This systematic review links heavy metal exposure and trace element deficiencies to oxidative stress, inflammation, and hormonal imbalance in PCOS, with implications for metabolic dysfunction and gut microbiome disruption.

This study evaluates the therapeutic potential of fecal microbiota transplantation (FMT) for treating female reproductive tract diseases, including PCOS, by restoring microbiota balance.

This review proposes a combination of fecal microbiota transplantation (FMT) and curcumin as a potential treatment for Polycystic Ovary Syndrome (PCOS). The hypothesis suggests these therapies could restore gut eubiosis, reduce inflammation, and improve metabolic dysfunction in PCOS patients.

This study demonstrates that resistant dextrin supplementation can improve metabolic and endocrine parameters in women with PCOS, offering a promising alternative to traditional therapies.

This review examines the link between PCOS and gut microbiota dysbiosis, highlighting how dietary and microbial interventions may improve clinical outcomes. The study underscores the potential of prebiotics, probiotics, and synbiotics as treatments.

This randomized trial evaluates the effects of synbiotic supplementation on hormonal, inflammatory, and metabolic parameters in women with PCOS. It shows significant improvements in androgen levels, insulin sensitivity, and inflammation.

What was studied? This randomized, double-blind, placebo-controlled clinical trial studied the effects of probiotic supplementation on pancreatic β-cell function and C-reactive protein (CRP) levels in women with polycystic ovary syndrome (PCOS). The aim was to explore how probiotics might influence insulin sensitivity, metabolic parameters, and inflammation markers in PCOS, which is often associated with insulin […]

What was studied? This study investigated the potential of repurposing FDA-approved drugs to treat Polycystic Ovary Syndrome (PCOS). Using bioinformatics tools, the authors analyzed protein-protein interactions (PPIs) related to PCOS and explored how certain drugs could interact with these proteins to potentially mitigate the pathogenesis of the disorder. The analysis particularly focused on identifying crucial […]

This study explores the use of berberine in combination with other drugs for treating PCOS, highlighting its effects on insulin resistance, androgen excess, and metabolic dysfunction.

This study identifies potential drug targets for PCOS, focusing on genes involved in insulin resistance and hormone signaling pathways. Findings could help develop more targeted treatments.

This study compared the effects of myo-inositol and metformin on insulin resistance, menstrual cycle regularity, and hyperandrogenism in women with PCOS. Both therapies were effective, with fewer side effects noted for myo-inositol.

The study evaluates the efficacy of Irosustat, STX140, and compound 1G as alternative treatments for PCOS, showing improvements in metabolic and hormonal profiles, with promising results on oxidative stress and inflammation markers. These compounds offer potential advantages over current PCOS therapies like metformin.

This review examines the role of metformin in treating PCOS-related infertility, highlighting its effectiveness in improving insulin sensitivity, reducing hyperandrogenism, and restoring ovulation. Metformin serves as a first-line therapy, offering significant benefits for women with anovulatory infertility due to PCOS.

This review discusses the role of metformin in treating PCOS-related infertility. It highlights its effectiveness in improving ovulation, reducing insulin resistance, and managing hyperandrogenism. Metformin is recommended as a first-line treatment for non-obese women with PCOS-related infertility, with benefits also seen in IVF and metabolic health.

OverviewMetronidazole is a synthetic nitroimidazole antimicrobial agent classified as a pharmaceutical antibiotic, widely used to treat anaerobic bacterial and protozoal infections. Its therapeutic application spans a range of systemic and localized conditions, including bacterial vaginosis, gastrointestinal infections, and surgical prophylaxis.[1][2][3] Due to its ability to selectively target anaerobic organisms and protozoa, metronidazole has become a […]

This review highlights the potential benefits of statin therapy in women with polycystic ovary syndrome (PCOS), showing improvements in metabolic dysfunction, hyperandrogenism, and cardiovascular risk factors. Statins may offer a dual benefit for PCOS management, though further research is needed for long-term clinical outcomes.

The study explored intermittent clomiphene citrate treatment (ICT) for women with PCOS who were resistant to standard CC treatment. ICT showed an 80.8% response rate, offering an effective and safer alternative to gonadotropin therapy with no risk of OHSS or multiple pregnancies.

This review outlines lactoferrin’s selective antimicrobial and prebiotic effects, showing how it inhibits pathogens while promoting specific probiotic strains through iron sequestration, metabolic modulation, and glycan delivery.

This study found a significant association between metronidazole use and neurologic toxicity, including encephalopathy and peripheral neuropathy, especially in older adults. Even low doses of metronidazole were linked to an increased risk of adverse events, emphasizing the need for careful monitoring and alternative therapies for high-risk patients.

This study uncovers complex mechanisms of metronidazole resistance in C. difficile, highlighting key genetic mutations and iron-dependent metabolic shifts that reduce drug efficacy. These findings inform future therapeutic strategies to address C. difficile infections.

This meta-analysis confirms that regional resistance patterns heavily influence H. pylori eradication success. In areas with low metronidazole and high clarithromycin resistance, PAM significantly outperforms PAC. These findings support microbiome-informed, resistance-guided therapy selection.

This large study confirms that prior metronidazole exposure significantly reduces H. pylori eradication rates with BQT. Extending treatment to 14 days restores effectiveness. The findings highlight the microbiome-relevant impact of antibiotic history and support individualized treatment planning.